肿瘤坏死因子超家族成员LIGHT及其受体研究进展  

Research Advances in LIGHT and Its Receptors

作　　者：邹颖[1,2] 王学民 顾军[2] 

机构地区：[1]上海市皮肤病医院皮肤与化妆品研究室,上海200443 [2]第二军医大学长海医院皮肤科,上海200433

出　　处：《医学综述》2015年第21期3902-3905,共4页Medical Recapitulate

基　　金：上海市卫生和计划生育委员会科研课题计划(201440366)

摘　　要：T细胞上可诱导表达的,与单纯疱疹病毒(HSV)的糖蛋白D竞争结合HSV侵入介导物(HVEM)的淋巴毒素类似物(LIGHT)是肿瘤坏死因子超家族的新成员之一,其通过HVEM、淋巴毒素β受体以及诱骗受体3结合发挥不同的生物学功能。可阻断HVEM依赖的HSV感染,在T细胞共刺激、T细胞亚群的分化增殖、树突状细胞活化、诱导和调节肿瘤细胞凋亡中发挥重要作用。LIGHT参与肿瘤免疫、移植物抗宿主病和多种免疫性疾病的发病机制。随着对于其研究的深入,有望成为肿瘤和相关炎性疾病治疗的新靶点。Homologous to lymphotoxins, exhibits inducible expression, and competes with herpes simplex virus（HSV） glycol-protein D for the herpes virus entry mediator（ HVEM ）, a receptor expressed by T lym- phocytes （LIGHT） is a newly discovered member of the tumor necrosis factor superfamily, which regulates T cell immune responses by signaling through the HVEM, the lymphotoxin 13 receptor （LT^R） and decoy recep- tor 3. LIGHT can block HVEM dependent HSV infection, playing an important role in T cell co-stimulation signals, the differentiation and proliferation of T cell subset, activation of dendritic cell and regulation apopto- sis of tumor cell. LIGHT is involved in the antitumor immunity, graft versus host disease （ GVHD）, and patho- genesis of multiple immunity diseases. These resuhs provide an encouraging profile for LIGHT as a potential target for treatment of the tumors and immunity diseases.

关 键 词：肿瘤坏死因子 共刺激 肿瘤免疫 移植物抗宿主病 

分 类 号：R392.11[医药卫生—免疫学]